Benzinga · Aug 6, 2026
Guggenheim Maintains Buy on Adicet Bio, Lowers Price Target to $90
Guggenheim analyst Yatin Suneja maintains Adicet Bio (NASDAQ:ACET) with a Buy and lowers the price target from $100 to $90.
AC
NASDAQ · ACET
Adicet Bio, Inc.
Healthcare · Biotechnology
$9.19
Down-$0.19 (-2.03%)
Updated Aug 23, 2026, 4:33 PM
SID Score
6.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 69.44M
- P/E ratio
- -0.36
- Dividend yield
- 0.00%
- 52-week range
- $6.01 – $9.84
- Volume
- 80.5K
- Avg. volume
- 192.48K
Price performance
ACET price history
1M range · 20 trading sessions · Daily adjusted prices
ACET closed at $9.19 after 20 trading sessions, up 14.02% for the selected period.
- Last close
- $9.19
- Period change
- +14.02%
- Period low
- $7.93
- Period high
- $9.49
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $9.42 | $9.63 | $9.10 | $9.19 | 80.5K |
| Aug 20, 2026 | $9.6155 | $9.6466 | $9.08 | $9.38 | 65.53K |
| Aug 19, 2026 | $8.99 | $9.60 | $8.99 | $9.49 | 84.85K |
| Aug 18, 2026 | $8.75 | $9.22 | $8.70 | $9.11 | 101.41K |
| Aug 17, 2026 | $8.46 | $8.99 | $8.46 | $8.74 | 93.23K |
| Aug 14, 2026 | $8.30 | $8.38 | $8.15 | $8.38 | 57.94K |
| Aug 13, 2026 | $8.35 | $8.50 | $8.25 | $8.26 | 51.26K |
| Aug 12, 2026 | $8.30 | $8.35 | $8.18 | $8.26 | 39.85K |
| Aug 11, 2026 | $8.15 | $8.29 | $7.925 | $8.23 | 65.76K |
| Aug 10, 2026 | $7.96 | $8.23 | $7.85 | $8.11 | 85.81K |
| Aug 7, 2026 | $8.12 | $8.2995 | $7.98 | $7.98 | 80.45K |
| Aug 6, 2026 | $8.71 | $8.88 | $7.42 | $7.93 | 179.95K |
| Aug 5, 2026 | $9.31 | $9.50 | $9.005 | $9.16 | 43.38K |
| Aug 4, 2026 | $9.35 | $9.47 | $9.19 | $9.21 | 95.4K |
| Aug 3, 2026 | $9.08 | $9.835 | $9.00 | $9.24 | 135.44K |
| Jul 31, 2026 | $8.97 | $9.21 | $8.545 | $9.11 | 123.47K |
| Jul 30, 2026 | $8.38 | $9.11 | $8.33 | $9.06 | 60.75K |
| Jul 29, 2026 | $8.28 | $8.43 | $8.09 | $8.30 | 92.15K |
| Jul 28, 2026 | $8.10 | $8.46 | $7.78 | $8.20 | 54.88K |
| Jul 27, 2026 | $7.84 | $8.26 | $7.74 | $8.06 | 107.92K |
Latest ACET news
The latest Smart Investors Daily articles mentioning ACET.
Stock researchCompany · Overview
ACET research
Overview
Company profile and research snapshot.
Company profile
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $32.50
- Implied upside
- —
- Analysts
- 14
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 6, 2026 | Guggenheim | Buy | — |
| Mar 23, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 13, 2026 | Guggenheim | Buy | — |
| Jan 21, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 6, 2026 | Canaccord Genuity | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 5, 2026
Adicet Bio Q2 EPS $(1.99) Beats $(2.03) Estimate
Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(1.99) per share which beat the analyst consensus estimate of $(2.03) by 1.97 percent. This is a 63.42 percent increase over losses of $(5.44) per share from the
businesswire.com · Nov 28, 2025
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on November 28, 2025. One individual was hired by Adicet in November 2025 and granted new hire non-qualified stock options to purchase 20,600 shares of Adicet's common stock with an exercise price of $0.65 per share, the closing price of.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
